Effect of Ketoconazole on Breathlessness

Completed · Phase 4 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

Beta-endorphins, which are naturally occurring narcotic substances, have been shown to alter the perception of breathlessness. Oral ketoconazole, an antifungal antibiotic, increases blood levels of beta-endorphins. The study hypothesis is that oral ketoconazole will reduce ratings of breathlessness induced by resistive breathing loads.

Key facts

Study ID

NCT01378520

Run by

Dartmouth-Hitchcock Medical Center

People needed

20

Starts

2011-06-01

Expected to finish

2012-02-01

Last updated by the study team

2018-06-01

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 50 years of age or older;
• diagnosis of COPD;
• current or former smoker of at least 10 pack-years;
• post-bronchodilator FEV1 greater than or equal to 30% predicted and less than or equal to 80% predicted; post-bronchodilator ratio < 70%

You may not qualify if…

• any concomitant disease that might interfere with study procedures;
• use of a drug that may cause a possible drug interaction with ketoconazole

Where it is running

• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.